FDA approved the dual combination bronchodilator Utibron Neohaler (indacaterol/glycopyrrolate) and the stand-alone monotherapy Seebri Neohaler (glycopyrrolate) – which is one component of Utibron Neohaler -- for patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.
As healthcare consumerism gains momentum, health plans need to change their offerings to keep up with consumer demands.
While many believe biosimilars have great potential, challenges remain.
These services can detect diseases earlier and prevent them altogether, but rates are lagging behind where they should be.
How advanced use of data and analytics can solve your biggest Star Ratings challenges
New research raises questions on supposed cost savings drive by mail order pharmacies.
Clinically Integrated Networks (CINs) are evolving quickly across the country in response to changing reimbursement trends and the move to value-based payments.
The FDA this week expanded the approved use of Yervoy (ipilimumab) to include a new use as adjuvant therapy for patients with stage III melanoma - lowering the risk that melanoma will return following surgery.
A new report looks specifically at spending on healthcare for the privately insured in the U.S in 2014. Here are the findings.
The increasing use of behavioral health medications and polypharmacy in children is concerning, but a new Massachusetts program may help.
During their headline session at the AMCP conference, presenters from Avalere Health shared their predictions for "three futures" in the healthcare market.
The high cost of specialty medications requires an array of management techniques, according to a recent presentation at the Academy of Managed Care Pharmacy Nexus 2015. Read more.
For patients with diabetes or high blood cholesterol, greater medication adherence is associated with a greater likelihood that the patient will achieve target biometric A1c and low-density lipoprotein levels, respectively, according to a poster session presented at the Academy of Managed Care Pharmacy meeting.
A new online library or knowledge portal, the Type 2 Diabetes Genetics Beta, has been launched to provide open-access searching of genetic and clinical information on type 2 diabetes.
A pharmacist-led telemonitoring program reduced blood sugar levels in diabetics, according to a new study.
A senior clinical consultant at Express Scripts says it's critical for healthcare executives to keep an eye on recently approved specialty medications. Here are six to watch.
A new report from ACAP details savings afforded Medicaid programs through managed care
During their session at the AMPC conference in Orlando, presenters identified several diabetes management approaches that are improving medication adherence.
Study: Florida’s tougher drug laws and monitoring program is positively impacting opioid prevention efforts.
Make your messaging stand out
FDA has approved buprenorphine (Belbuca, Endo Pharmaceuticals) buccal film for use in patients with chronic pain.
FDA has approved idarucizumab (Praxbind, Boehringer Ingelheim) as the first reversal agent for Pradaxa.
When two new treatments for idiopathic pulmonary fibrosis (IPF) were approved by FDA last year, there was not much data available on the drugs in patient populations.
A senior clinical consultant at Express Scripts says it's critical for healthcare executives to keep an eye on how specialty medications in the pipeline will impact these four conditions.
The effort to secure provider status for pharmacists continues on a federal and state level, and it may be gaining more traction than ever.
At the Academy of Managed Care Pharmacy Nexus 2015, two presenters identified legislative and regulatory changes that could have a big impact on managed care.
The FDA approved Onivyde (irinotecan liposome injection), in combination with fluorouracil and leucovorin, to treat patients with advanced (metastatic) pancreatic cancer who have been previously treated with gemcitabine-based chemotherapy.
FDA approved Strensiq (asfotase alfa) as the first approved treatment for perinatal, infantile and juvenile-onset hypophosphatasia (HPP).
FDA approved patiromer (Veltassa, Relypsa) oral suspension for the treatment of hyperkalemia. Hyperkalemia is the condition when blood potassium levels are higher than normal in the kidneys, which can lead to abnormal heart rhythms or sometimes death.
